摘要
Abstract
Objective To systematically review research on the pharmacoeconomics of schizophrenia with risperidone,so as to provide a reference for the economic evaluation and clinical treatment decision-making of risperidone.Methods Chinese and English databases such as PubMed,the Cochrane Library,Web of Science,and Embase database,CNKI,Wanfang database,VIP,were searched for economic evaluation literature on the use of risperidone for the treatment of schizophrenia.References were screened according to inclusion and exclusion criteria,and extracting relevant information,the quality of including literature was evaluated by using the CHEERS 2022 quality assessment table to include the perspective of the basic information,literature quality,model structure and elements,health status,utility values,health outcomes,and economic evaluation.Results 74 literatures were included in this study,including 41 Chinese literatures and 33 English literatures.the overall quality of the literature was moderate,with the majority of literature focusing on cost-effectiveness analysis and cost-utility analysis using decision Decision Tree models and Markov models.The perspective of the literature included in this study mainly focuses on healthcare systems and medical care systems,therefore the costs primarily consider direct costs,with data sourced from healthcare management departments or pharmaceutical websites;the effectiveness values mainly used the PANSS scoring scale to calculate the effectiveness rate as the outcome indicator,and utility values all used quality-adjusted life years(QALYs).Palmidone long-acting injection had a significant economic advantage over risperidone long-acting injection in the treatment of schizophrenia;risperidone had an economic advantage over other oral antipsychotic medications in the treatment of first-episode schizophrenia and recurrent schizophrenia;there was no consensus on the economic value of risperidone compared to aripiprazole,ziprasidone,or quetiapine fumarate in the treatment of schizophrenia.Conclusion Researchers relied on medical institution data to conduct retrospective studies,which may have problems such as small sample size and insufficient representativeness,and should be promoted to conduct large-sample studies in China.Future studies can improve the model structure,model validation,utility measurement,etc.Meanwhile,studies based on real-world data should be actively explored to further demonstrate the pharmacoeconomic value of risperidone versus aripiprazole,ziprasidone,and quetiapine fumarate in the treatment of schizophrenia.关键词
利培酮/精神分裂症/药物经济学评价Key words
Risperidone/Schizophrenia/Pharmacoeconomic evaluation分类
医药卫生
